Powered By
More great news from the clinical trial frontlines - FDA approved bispecific antibody therapies such as teclistamab, elranatamab, talquetamab and now recently approved linvoseltamab, may soon find themselves accompanied by trispecific (and quadspecific) antibodies. The effectiveness of these new drugs, which have the capability to attach themselves to multiple binding sites on the MM cells, had an overall response rate of 100% with patients and a complete response rate of 70.4%.
Jamie and others, I have been on teclistamab for 7 cycles now and my oncologist is saying remission and is cutting the number of future treatments in half. I am very pleased with this since nothing else worked for very long!
I am presently in a clinical trial with elranatamab after CAR-T cell infusion in March. Only side effect I had was a fever the night of the T cell infusion and a fever the night of the first elranatamab injection. I just recently have dry, flaky skin on my face and hands. I was told today that it is a side effect from this drug also. It’s manageable. This will augment the T cells to kill any cancer cells. It runs for 6 months and I am feeling positive about the outcome. The providers say I’m doing great. Bone marrow biopsy is negative!!
Great news for you! I’m starting the opening checks for a chance at a CAR T clinical trial, tomorrow.
Cheryl,
That’s wonderful news!!!!
Praise be to God!!!!!
Martin, that’s great news!!
Join
Your Privacy Choices
